Recipharm has invested €18m to expand its blow fill seal (BFS) capacity at its plant in Kaysersberg, France.
The Swedish contract development and manufacturing organisation (CDMO) will install a new blow fill seal high speed filling and packaging line, increasing the total number of lines from seven to eight to meet growing demand for the service.
Preparations will also be made to add a further three filling lines over the coming years, more than doubling the size of the CDMO’s operations from 2000 m2 to 4150 m2, and increasing its blow fill seal capacity by 50%.
The first of the four planned filling lines will allow Recipharm to support more drug developers with the aseptic processing of sterile liquids such as eye care and ear drops into plastic containers.
Yves Buelens, General Manager at Recipharm’s Kaysersberg site, said the firm has been experiencing increased demand for its blow fill seal services from customers in the US, Turkey, Australia and Canada and the new filling line will help it meet this growing need.
'The increased capacity will position us well for future growth and allow us to take on new projects from new customers more swiftly,' added Buelens.
'With the site’s Big Pharma heritage, we are ideally placed to meet the highest quality and regulatory requirements and are committed to investing in the facility to ensure we can continue to deliver the best possible service.'
Recipharm serves more than 250 customers globally, offering various dosage forms, production of clinical trial material and APIs and pharmaceutical product development. The Kaysersberg site, located in Alsace, France, is a sterile facility specialising in blow fill seal technology for sterile liquids. The site manufactures single dose units and has an advanced aseptic process for sterile liquid packaging applications in plastic containers.
